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ABSTRACT
American Indian/Alaska Natives (AI/AN) patients at an urban residential chemical 
dependency treatment center participated in a viral hepatitis prevention project.  Project 
activities integrated into patients’ treatment programs included viral hepatitis and 
human immunodeficiency virus (HIV) risk factor screening, education and counseling, 
laboratory testing, and hepatitis A and B vaccination.  Of 928 AI/AN admissions, 585 
(63%) completed risk factor screening assessment.  Of these, 436 (75%) received at 
least one vaccination, viral hepatitis testing, or both.  Of 322 patients tested, 91 (28%) 
were hepatitis C virus (HCV) antibody positive.  Lack of pre-existing immunity to 
vaccine-preventable viral hepatitis infection was common: 132 (45%) were susceptible 
to hepatitis A and 224 (70%) were susceptible to hepatitis B infection.  Chemical 
dependency treatment centers serving urban AI/AN provide important opportunities 
for implementing viral hepatitis prevention programs for high-risk populations and for 
improving ongoing efforts to reduce the disparate impact of chronic liver disease in AI/
AN people.   
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BACKGROUND
Viral hepatitis caused by infection with hepatitis A virus, hepatitis B virus and hepatitis C virus 
is a major public health problem (Buffington & Jones, 2007).  In 2007, there were an estimated 
25,000 new infections of hepatitis A, 43,000 new infections of hepatitis B, and 17,000 new hepatitis 
C infections (CDC, 2009).  Although safe and effective vaccines have been available for hepatitis B 
since 1981 and for hepatitis A since 1995 (CDC, 2009), no vaccine exists against hepatitis C.  Hepatitis 
C virus (HCV) infection is now the most common chronic blood borne infection in the United States 
(Armstrong, et al. 2006 and Neumeister, et al. 2007).  
Chronic liver disease and viral hepatitis infection have historically been areas of health disparities 
for American Indians and Alaska Natives (AI/AN).  Major gains have recently been made in hepatitis 
A and B prevention in AI/AN people, in whom the incidence of both acute hepatitis A and acute 
hepatitis B have approached national rates (CDC, 2009); but hepatitis C, either alone or with alcohol 
use/abuse, remains a major contributor to chronic liver disease among American Indians (Bialek, 
et al. 2008).  The chronic liver disease mortality rate among AI/AN is more than twice that of Whites 
and African Americans nationwide, and remained unchanged throughout the 1990s, unlike rates for 
other racial/ethnic populations, which have demonstrated declines (Vong & Bell, 2004).  
The prevalence of HCV infection among AI/AN is not well understood.  The National Health and 
Nutrition Examination Survey conducted between 1999 and 2002 estimated a prevalence of 1.6% 
of HCV infection in the United States, which was higher among men than women (Armstrong, et al. 
2006).  However, these results do not include estimates for AI/AN.  Due to the substantial burden of 
chronic liver disease among AI/AN, there is urgent need to develop a better understanding of HCV 
epidemiology among AI/AN populations. 
American Indians/Alaska Natives living in urban areas across the country typically lack any kind 
of unifying surveillance system.  As a result, a paucity of information exists about viral hepatitis 
epidemiology, risk factors, and prevention efforts in these populations.  Also, rates of substance use/
abuse among urban AI/AN can be difficult to describe, although surveys conducted by the Substance 
Abuse and Mental Health Services Administration indicate higher rates of alcohol use and illicit 
drug use disorders among AI/AN as a whole compared to other populations (SAMHSA, 2007).  This 
information strongly suggests that the burden of viral hepatitis among urban AI/AN is high. 
Various regional studies in the United States have shown prevalence of HCV infection and related 
risk factors in urban AI/AN higher than the nationally reported prevalence of 1.6% (Armstrong, et al. 
2006).  An urban Indian clinic in Omaha, Nebraska reported HCV infection among 8.6% of those AI/
AN tested.  Significant risk factors associated with HCV infection included injection drug or cocaine 
use, a sexual partner with HCV, and a tattoo for more than five years (Neumeister, et al. 2007).  
Among a small sample of American Indian women receiving prenatal care in Phoenix, Arizona, 3.1% 
were found to be infected with HCV (Wilson, 2004).  Another study among American Indians in the 
Southwest found that the majority of patients with confirmed HCV diagnosis reported injection drug 
use (Norton, et al. 2009). 
Data exist that support the integration of prevention and education services for viral hepatitis 
and human immunodeficiency virus (HIV) with existing programs serving high-risk patients, and 
numerous examples have demonstrated the benefits of this approach (Buffington & Jones, 2007).  
Counseling and testing sites, reproductive health clinics, substance abuse treatment programs, and 
correctional facilities all provide opportunities for prevention intervention. 
The Healthy Liver Program in Minneapolis established a method for addressing viral hepatitis 
infections among patients who present for chemical dependency treatment.  Their experience 
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confirms that patients entering chemical dependency treatment have a high risk for HCV infection 
and low rate of immunity to hepatitis A and B virus infections (Hagedorn, et al. 2007).  Another 
program in San Diego successfully integrated services for viral hepatitis, sexually transmitted 
infection, and HIV into a drug rehabilitation program: 83% of enrollees participated in the program 
which offered hepatitis B vaccination, hepatitis B and C serologic testing, sexually transmitted 
infection screening, and HIV counseling and testing (Gunn, et al. 2005). 
While examples in the literature exist of such integrated programs, there are few if any examples 
of programs serving urban AI/AN.  This article describes the development of our project integrating 
viral hepatitis prevention services into a residential chemical dependency treatment center targeting 
urban AI/AN.  We describe methods used to integrate viral hepatitis prevention services and report 
results of risk factor assessment and laboratory testing.
METHODS
Project Location
The project was located in Seattle, Washington at the Seattle Indian Health Board, a private, 
non-profit 501(c)(3) community health center.  The Seattle Indian Health Board is comprised of the 
Leschi Clinic, a full-service primary medical and dental health care center; the Thunderbird Treatment 
Center, which provides residential chemical dependency treatment targeting adult AI/AN living in 
the Seattle-King County area; and the Urban Indian Health Institute, one of 12 Tribal Epidemiology 
Centers partially funded by the Indian Health Service to manage public health information systems, 
investigate diseases of concern, manage disease prevention programs, and coordinate activities with 
other public health authorities.  
Beginning in 2001, the Seattle Indian Health Board received funding from the CDC and support 
from the Indian Health Service to develop a viral hepatitis integration project for patients residing at 
the Thunderbird Treatment Center.  The treatment facility offers an intensive residential program (28 
days) and a limited long-term residential program (six months), serving 600-700 patients per year.  
The Seattle Indian Health Board’s ability to provide chemical dependency treatment, clinical services, 
and public health support provided an outstanding opportunity to describe the epidemiology of 
viral hepatitis and determine risk factors for this population and, most importantly, improve services.  
The following activities were integrated into the patients’ treatment programs: viral hepatitis and 
HIV risk factor screening; viral hepatitis and HIV education and counseling; viral hepatitis and HIV 
laboratory testing; and hepatitis A and B vaccination (Figure 1).  We present results from June 2003 – 
September 2007 for the viral hepatitis portion of the project.
Risk Factor Screening and Education
We attempted to screen all patients admitted to Thunderbird Treatment Center for risk factors 
associated with viral hepatitis and HIV within a few days of admission.  The screening process 
included a personalized risk assessment for viral hepatitis and HIV, a standard part of the medical 
intake for all admissions.  Risk factor screening questions were asked either by a health educator 
or intake nurse, who provided education and counseling about individual risk of viral hepatitis; 
modification of the counseling occurred based on individual risk factors and/or patient questions.  In 
addition to one-on-one sessions and individualized risk factor screenings, patients received general 
education about viral hepatitis and HIV via a mandatory monthly group education session; which 
included viewing a HCV video followed by a group discussion.
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Risk factors included: injection drug use (ever), incarceration for more than one year, sex in 
exchange for money or drugs, multiple sex partners (more than two in the last six months), sexually 
transmitted infections, tattoos, and receipt of blood or blood products prior to 1992.  
Vaccination
After completing the risk factor screening and educational session, hepatitis A and hepatitis B 
vaccines were provided at no cost to all patients admitted to Thunderbird Treatment Center.  Previous 
hepatitis vaccinations administered at other locations/clinics prior to admission were only recorded 
and documented if patient had proof of vaccination record.  Personal vaccination records also 
were provided to patients and they were encouraged to return for follow-up at the Leschi clinic to 
complete the hepatitis A and B vaccine series.  
Testing
A. Specific Methods:
Upon completion of the risk factor screening and educational session, all patients admitted to 
treatment were offered serum testing for chronic viral hepatitis and HIV.  Patients serum samples 
were sent to a contract laboratory for testing for: antibodies to HCV (anti-HCV) using the enzyme 
immunoassay (EIA) test; immunoglobulin G antibody to hepatitis A virus (anti-HAV IgG); hepatitis B 
surface antigen (HBsAg); hepatitis B surface antibody (anti-HBs); total hepatitis B core antibody (anti-
HBc); and antibodies to HIV-1.  We defined cases of current or past hepatitis B virus infection and 
immunity according to standard interpretations of hepatitis B serologic markers (CDC, 2008).  
B. Follow-up/patient care:
Results and post-test counseling were provided to patients by a health educator, nurse or 
medical provider.  Post-test counseling sessions included education with focus on a risk reduction 
Figure 1.   Viral Hepatitis Integration Project Activities Integrated into Existing 
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plan.  Hepatitis A and B vaccines were offered again if the patient initially declined and if appropriate.  
Patients with positive results were recommended to receive confirmatory testing and if appropriate, 
a specialty referral. 
Data collection and analysis
We collected the following data from patient charts: demographics (gender, race, age), responses 
to risk factor screening questions (see above), receipt of vaccinations, and testing results.  All 
data were stored in a secure Access (Microsoft, Redmond, Washington) database, and analyzed 
and reported to funding agencies on a quarterly basis.  Only vaccines with recorded dates were 
considered to have been given, and only patients with recorded test results were considered to have 
been tested.  Any indeterminate test results were considered negative for this analysis if confirmatory 
testing was not completed.  Only those patients with responses to at least two or more risk factor 
questions were considered to have completed the risk factor assessment.  Gender, race and age were 
determined by self-report at the time of admission to the treatment program.  For those patients 
who were admitted two or more times during the project period, only the first admission data were 
analyzed.  
All available data from the database were included in the logistic regression models in order 
to maximize statistical power, including for those patients that did not complete a full risk factor 
screening assessment.  Indicators found to be significant in univariate analysis were entered in 
logistic regression models which included age and injection drug use; tests of significance were 
computed after controlling for these known risks.  Odds ratios were considered significant at the <.05 
level.  Stata version 9.0 (StataCorp LP, College Station, Texas) was used for all analyses.  
The project was reviewed and approved by the Portland Area Indian Health Service Institutional 
Review Board.
RESULTS
Patients Served 
A total of 928 persons admitted to the Thunderbird Treatment Center during the project period 
self-identified as AI/AN.  Of these, 585 (63%) unduplicated individuals participated by completing a 
risk factor screening assessment.  The remaining 343 patients (37%) did not participate due primarily 
to refusal or non-contact during the intake process.  Of the 585 individuals, 425 (73%) were male.  The 
mean age was 36.7 years (range 18 to 69 years) for men and 36.6 years (range 18 to 61) for women.
Services Provided
A total of 436 patients (75% of those completing risk factor assessment) received at least one 
vaccination, viral hepatitis testing, or both (Figure 2).  Three hundred (51%) received at least one 
hepatitis A vaccine and 322 (55%) received at least one hepatitis B vaccine.  The majority of patients 
after August 2005 received the combined Twinrix (GlaxoSmithKline, London, United Kingdom) 
vaccine.  Due to the length of stay in treatment, most patients did not complete the full series of the 
hepatitis A and hepatitis B vaccination while a patient at Thunderbird.  Three-hundred twenty three 
(55%) consented to viral hepatitis testing; most received the full chronic viral hepatitis panel.  
Test Results
Of 322 participants who consented to blood testing and completed the risk factor assessment, 91 
(28%) were hepatitis C virus antibody positive.  Fifty (16%) showed evidence of past hepatitis 
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Figure 2.   Distribution of Services Delivered to 585 AI/AN Patients
B exposure (anti-HBc), and 96 (30%) were immune to hepatitis B through either exposure or 
vaccination (anti-HBs).  No patients were chronically infected with hepatitis B infection (HBsAg).  
One hundred fifty- nine (55%) showed evidence of immunity to hepatitis A, either through past 
vaccination or exposure.  Among those who tested positive for hepatitis C infection, 32 (38%) were 
susceptible to hepatitis A and 60 (67%) were susceptible to hepatitis B (Table 1).  
Risk Factor Results 
The 585 participants who completed the risk factor assessment reported risks for hepatitis 
infection included injection drug use (186/585, 32%), prior incarceration for greater than one year 
(131/579, 23%), receipt of blood product before 1992 (5/81, 6%), traded sex for money or drugs 
(70/581,12%), tattoos (335/580, 58%), history of sexually transmitted infections (164/576, 28%), and 
Table 1. Serum Test results in 323 AI/AN Patients
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multiple sex partners (more than two in the last six months) (109/580, 19%).  Because participants 
were free to answer or not answer any questions, not all participants answered all questions.  
Risk factors shown to be associated with a positive HCV EIA included the following: injection 
drug use, prior incarceration for greater than one year, receipt of a blood product before 1992, and 
sex traded for money or drugs.  When controlling for age and injection drug use using conditional 
logistic regression, incarceration for greater than one year was the only risk factor which remained 
significant.  Injection drug use also remained highly significant after controlling for age (Table 2). 
     Table 2. Risk Factor Results by Anti-HCV EIA Status
DISCUSSION
This project demonstrates the successful integration of viral hepatitis risk factor assessment, 
screening, counseling, and vaccination activities into a residential chemical dependency treatment 
program serving a high-risk urban AI/AN population. 
Twenty-eight percent of the AI/AN patients tested at this urban residential chemical dependency 
treatment program had positive anti-HCV EIA test results.  As our project was designed to 
improve clinical services at the residential chemical dependency treatment center, we caution its 
interpretation as a measure of overall or specific AI/AN population prevalence.  Our results may not 
apply to other rural or urban AI/AN populations, or to other AI/AN chemical dependency treatment 
populations.  Since our program was meant to provide initial screening only, we did not perform 
confirmation of anti-HCV EIA results and did not measure presence of serum HCV RNA.  These further 
clinical tests were to be performed later, generally after discharge from the residential chemical 
dependency treatment program, as part of ongoing medical care. 
As in other populations, injection drug use was the primary risk factor for presence of anti-HCV 
EIA in our patients.  Nearly one-third of AI/AN patients who answered the risk assessment questions 
reported at least one episode of injection drug use, and 80% of those testing positive for anti-HCV 
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reported injection drug use.  This contributes to the mounting evidence that injection drug use is the 
most important HCV risk factor in AI/AN people, as it is in other populations.  Moreover, AI/AN may be 
more likely to use injection drugs than other populations (SAMHSA, 2007; Rutman, et al. 2008).  Given 
the known disproportionate burden of chronic liver disease in AI/AN populations and the likely large 
contribution of HCV infection to this burden, reduction of chronic liver disease death rate in AI/AN 
people will require increased efforts around the prevention and treatment of chemical dependency. 
Prior incarceration for more than one year also was independently associated with HCV infection 
among patients; this association remained significant after controlling for injection drug use and 
age.  Studies have shown high rates of HCV among prison populations; of note however, is that 
previous incarceration is generally not considered an independent risk factor for HCV infection (CDC, 
2007).  One estimate indicated that 39% of all Americans with chronic HCV infections were released 
from jail or prison during the previous year (CDC, 2003).  Some proportion of the risk attributed to 
incarceration may be due to underreporting of injection drug use by those incarcerated.  
In most analyses, male gender is associated with increased prevalence of HCV (CDC, 2001; CDC, 
2007; Neumeister, et al. 2007; Armstrong, et al. 2006), but we did not find this association in our 
project.  In the general population, men are more likely than women to report a history of injection 
drug use, contributing to their higher rate of HCV infection (SAMHSA, 2007).  Interestingly, among 
the patients admitted to the residential chemical dependency treatment program, women were 
somewhat more likely to report injection drug use than men (37.9% vs. 30.0%, p=.07).  Again, the 
highly selected nature of our patient population should be considered when interpreting these 
results. 
Immunity to hepatitis A virus - through vaccination or infection - was far from universal in this 
group of AI/AN adults (55%).  Rates of hepatitis A infection have traditionally been high among AI/
AN (CDC, 1999; CDC, 2007), but recent immunization efforts in these communities have drastically 
reduced the incidence of hepatitis A overall (Bialek, et al. 2004).  This project demonstrated, however, 
that groups of high-risk AI/AN adults are being missed in these efforts and that on-going vaccination 
programs to reach them are still needed. 
The majority of patients tested (70%) also showed susceptibility to hepatitis B infection, and 
would benefit from vaccination.  The CDC currently recommends universal vaccination against 
hepatitis B for all children, and for high-risk adults (CDC, 2006).  Evidence from this project indicates 
that this group of high-risk adults may be missed in current vaccination efforts, and targeted 
programs to reach them are still urgently needed.  Based on the findings from this project, hepatitis 
A and hepatitis B vaccine delivery in settings such as a residential treatment center is an effective 
strategy to reduce the likelihood of incident viral hepatitis in these high-risk patients.
In addition to the HCV testing limitations discussed, other limitations need to be considered 
when interpreting findings.  We were not able to screen and conduct risk factor assessments on every 
patient admitted into Thunderbird Treatment Center, therefore non-participants may differ than 
those who participated in the activities.  Other similar facilities could improve upon this percentage 
by having a clear system in place which assures that the risk factor screening assessment occurs at 
the same time as the intake.
Of note, due to the length of stay in treatment, most patients did not complete the full series of 
the hepatitis A and hepatitis B vaccination.  However, one of the strengths of the project was the 
success of capturing high-risk patients for a first dose of vaccine, as even one dose has been shown 
to be beneficial.  Another limitation was that before 2006, no information about year of blood 
transfusion was collected; thus we had to omit this variable from our analysis for patients reporting 
transfusion before 2006.  Finally, as stated earlier, all results presented here may not apply to AI/AN 
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participating in other chemical dependency treatment programs.  
       Interest in viral hepatitis prevention services was high among patients at this residential 
chemical dependency treatment center, and most chose to accept either vaccination and/or 
testing when offered.  It is important to connect chemical dependency and clinical services in 
high-risk populations such as ours, and this project showed that integration was possible and 
successful.  Our serology results showed an unmet need for hepatitis A and B vaccination on patient 
entry, and suggest that a strategy of vaccine delivery without pre-vaccination testing may be the 
most appropriate one for this and similar settings where at-risk patients will be served.  Chemical 
dependency treatment centers serving urban AI/AN are excellent locations in which to implement 
viral hepatitis prevention programs, and can contribute directly to ongoing efforts to reduce the 
disparate impact of chronic liver disease among AI/AN populations. 
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